These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23064737)

  • 21. Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography (PET)-based parameters in neoadjuvant chemoradiation treatment of esophageal carcinoma.
    Ma JB; Chen EC; Song YP; Liu P; Jiang W; Li MH; Yu JM
    Asian Pac J Cancer Prev; 2013; 14(4):2477-81. PubMed ID: 23725159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.
    Cong L; Wang S; Gao T; Hu L
    Jpn J Clin Oncol; 2016 Dec; 46(12):1118-1126. PubMed ID: 27702836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of FDG-PET in screening of synchronous cancer of other organs in patients with esophageal cancer.
    Miyazaki T; Sohda M; Higuchi T; Tanaka N; Suzuki S; Sakai M; Yokobori T; Nakajima M; Fukuchi M; Tsushima Y; Kato H; Kuwano H
    Anticancer Res; 2014 Jan; 34(1):283-7. PubMed ID: 24403475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limitations of FDG-PET and FDG-PET with computed tomography for detecting synchronous cancer in pharyngeal cancer.
    Suzuki H; Hasegawa Y; Terada A; Ogawa T; Hyodo I; Suzuki M; Nakashima T; Tamaki T; Nishio M
    Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1191-5. PubMed ID: 19015450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDG-PET nodal staging does not correlate with histopathological nodal stage for oesophageal cancers.
    Devadas M; Mittal A; Lin M; Cosman P; Ziazaris W; Wilson R; Das A; Merrett N
    Int J Surg; 2015 Aug; 20():113-7. PubMed ID: 26118612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early response evaluation of neoadjuvant therapy with PET/MRI to predict resectability in patients with adenocarcinoma of the esophagogastric junction.
    Belmouhand M; Löfgren J; Johannesen HH; Baeksgaard L; Gutte H; Tariq K; Achiam MP
    Abdom Radiol (NY); 2019 Mar; 44(3):836-844. PubMed ID: 30467723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there a role for PET/CT with esophagogastric junction adenocarcinoma?
    Fuster D; Mayoral M; Rubello D; Pineda E; Fernández-Esparrach G; Pagès M; Colletti PM; Pons F
    Clin Nucl Med; 2015 Mar; 40(3):e201-7. PubMed ID: 25546207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation-Induced Esophagitis Masquerading as Disease Progression in Case of Esophageal Carcinoma: A Diagnostic Dilemma Solved on Follow-up FDG PET/CT.
    Mukherjee A; Chakraborty PS; Behera A; Bal C; Kumar R
    Clin Nucl Med; 2015 Jul; 40(7):e380-1. PubMed ID: 25706793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of
    Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
    J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
    J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma.
    Port JL; Lee PC; Korst RJ; Liss Y; Meherally D; Christos P; Mazumdar M; Altorki NK
    Ann Thorac Surg; 2007 Aug; 84(2):393-400; discussion 400. PubMed ID: 17643605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indications and Limitations in the Management Algorithm of Patients With Esophageal Adenocarcinoma: Positron Emission Tomography Computed Tomography.
    Fisichella PM
    JAMA Surg; 2015 Jun; 150(6):562. PubMed ID: 25902411
    [No Abstract]   [Full Text] [Related]  

  • 33. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
    Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of pre-treatment 18F-FAMT PET to predict patient survival in squamous cell carcinoma of the esophagus treated by curative surgery.
    Sohda M; Sakai M; Honjyo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Miyazaki T; Fukuchi M; Higuchi T; Tsushima Y; Kuwano H
    Anticancer Res; 2014 Jul; 34(7):3623-8. PubMed ID: 24982378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
    Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
    Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Yamakita I; Kurokawa T; Okada M
    Ann Thorac Surg; 2016 Oct; 102(4):1132-9. PubMed ID: 27319990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carcinoma of esophagus: radiologic diagnosis and staging.
    Kumbasar B
    Eur J Radiol; 2002 Jun; 42(3):170-80. PubMed ID: 12044696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic values of mid-radiotherapy
    Kim N; Cho H; Yun M; Park KR; Lee CG
    Radiat Oncol; 2019 Feb; 14(1):27. PubMed ID: 30717809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.